Irine Vodkin, MD
Gastroenterology · La Jolla
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Regents of the University of California · 2,047 clinicians in this group
Looking this up.
Hospitals listed: UC San Diego Health Hillcrest - Hillcrest Med Ctr. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Vodkin’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A113664 · Current
Licensed to practise in California · since 2010 · expires 2028-05-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UC San Diego Health Hillcrest - Hillcrest Med CtrSan Diego, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of Moores Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 105.39 (74.34 to 136.44) · 381 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.597, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.618, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.376, Oct 2024 – Sep 2025
See every measure and the patient survey for UC San Diego Health Hillcrest - Hillcrest Med Ctr
Behind the star rating — Deaths: 6 better, 2 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 105.39 (74.34 to 136.44) · 381 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.597 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.618 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.376 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.83 (0.11 to 1.54) · 3,862 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.84 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 130 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.2 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.1 · 183 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.8 · 510 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11 · 696 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 435 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 5,739 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.32) · 12,387 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.44) · 13,596 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.59 (3.24 to 5.94) · 4,389 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.04 (0 to 2.12) · 2,419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.26 (1.23 to 3.29) · 4,116 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.93 (6.61 to 13.25) · 2,232 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.31 (5.24 to 9.38) · 2,410 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.32 (1.07 to 3.56) · 1,286 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.38 (0.02 to 0.75) · 11,838 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 181 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.672 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 302 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.3 · 891 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 216 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 5.9 · 620 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 12 · 731 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.7 · 946 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.9 (4.8 to 7) · 1,507 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.3 (10.7 to 14) · 1,507 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.1 · 191 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.7 · 177 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 204 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.4 (8.5 to 13) · 4,116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1) · 2,130 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,680 patients answered, 16% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$44,732
Medicare paid this office $44,732 for 194 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $12,112 | $96 |
| Long return visit (40+ min) | 45 | $8,889 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $4,629 | $136 |
| Return visit (30+ min) | 38 | $4,206 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,445 | $64 |
See all 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $12,112 | $96 |
| Long return visit (40+ min) | 45 | $8,889 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $4,629 | $136 |
| Return visit (30+ min) | 38 | $4,206 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,445 | $64 |
| New patient visit (45+ min) | 12 | $1,464 | $122 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,198 | $92 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,147 | $88 |
| Return visit (30+ min) | 12 | $972 | $75 |
Procedures Medicare counted
| Colonoscopy | 11 | More than 41% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 38 | More than 59% of doctors who do this |
Who their Medicare patients are
194 Original Medicare patients in 2024. Average age 66 · Under 65 27% · Women 49% · Also on Medicaid 47% · Health risk score 2.95. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 48% · Chronic kidney disease 39% · Heart failure 29% · Coronary heart disease 27% · Depression 27% · Atrial fibrillation 22% · Cancer 17% · COPD 13% · Stroke 12% · Dementia 6%.
The office billed $239,848, Medicare allowed $57,470 and paid $44,732; for 743 services of 31 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 194 | 743 | 66 | 2.95 | $239,848 | $44,732 |
| 2023 | 205 | 433 | 66 | 2.97 | $221,904 | $42,742 |
| 2022 | 258 | 2,143 | 67 | 3.14 | $276,469 | $55,963 |
| 2021 | 238 | 708 | 65 | 3.30 | $319,389 | $68,763 |
| 2020 | 180 | 489 | 65 | 3.76 | $198,221 | $41,254 |
| 2019 | 232 | 674 | 64 | 3.37 | $242,900 | $57,556 |
| 2018 | 259 | 807 | 65 | 3.39 | $333,350 | $68,425 |
| 2017 | 253 | 718 | 65 | 3.10 | $308,532 | $59,691 |
| 2016 | 194 | 558 | 64 | 2.60 | $228,568 | $45,738 |
| 2015 | 86 | 167 | 64 | 2.77 | $77,551 | $15,290 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $7,272 | $96 |
| Long return visit (40+ min) | 28 | $6,731 | $146 |
| Return visit (30+ min) | 43 | $4,394 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,088 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $3,193 | $65 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $2,016 | $101 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,925 | $107 |
| Return visit (30+ min) | 26 | $1,851 | $69 |
| New patient visit (45+ min) | 11 | $1,462 | $133 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,285 | $86 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 15 | $65 | $4 |
2022: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $11,326 | $85 |
| Long return visit (40+ min) | 46 | $9,695 | $133 |
| Return visit (30+ min) | 55 | $6,107 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,756 | $160 |
| New patient visit (45+ min) | 26 | $3,346 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $2,721 | $59 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,550 | $97 |
| Return visit (30+ min) | 20 | $1,537 | $70 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,451 | $112 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,354 | $104 |
| Short return visit (20+ min) | 14 | $941 | $63 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 22 | $111 | $4 |
2021: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $18,317 | $86 |
| Long return visit (40+ min) | 49 | $12,720 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,958 | $161 |
| Long return visit (40+ min) | 35 | $4,648 | $119 |
| Return visit (30+ min) | 38 | $4,240 | $99 |
| Return visit (30+ min) | 37 | $3,637 | $81 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,604 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,139 | $59 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 21 | $2,028 | $92 |
| New patient visit (45+ min) | 13 | $1,712 | $132 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,488 | $88 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 30 | $144 | $4 |
2020: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $12,872 | $79 |
| Long return visit (40+ min) | 33 | $5,903 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,675 | $160 |
| Return visit (30+ min) | 21 | $2,144 | $86 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,832 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $1,696 | $61 |
| Return visit (30+ min) | 22 | $1,457 | $61 |
| Long return visit (40+ min) | 12 | $1,316 | $94 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $992 | $83 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 28 | $128 | $4 |
2019: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $12,541 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 62 | $7,987 | $61 |
| Long return visit (40+ min) | 29 | $5,686 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,374 | $168 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $4,204 | $114 |
| Return visit (30+ min) | 35 | $3,798 | $90 |
| Return visit (30+ min) | 46 | $3,678 | $66 |
| Long return visit (40+ min) | 23 | $2,496 | $92 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $1,836 | $92 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $920 | $84 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 15 | $164 | $10 |
2018: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $16,263 | $80 |
| Long return visit (40+ min) | 37 | $8,999 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $6,629 | $55 |
| Return visit (30+ min) | 47 | $5,133 | $86 |
| Long return visit (40+ min) | 31 | $3,377 | $84 |
| Tying of dilated veins of stomach and/or esophagus using a flexible endoscope | 13 | $3,152 | $185 |
| Return visit (30+ min) | 42 | $2,896 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,527 | $149 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,267 | $108 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $1,952 | $81 |
| Biopsy of large bowel using a flexible endoscope | 18 | $1,878 | $104 |
| New patient visit (60+ min) | 14 | $1,862 | $133 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,434 | $84 |
| Short return visit (20+ min) | 11 | $590 | $54 |
2017: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $14,276 | $83 |
| Long return visit (40+ min) | 36 | $7,998 | $113 |
| Return visit (30+ min) | 44 | $6,310 | $85 |
| Return visit (30+ min) | 52 | $3,996 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,329 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,878 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $1,996 | $154 |
| New patient visit (45+ min) | 21 | $1,971 | $94 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $1,803 | $86 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $1,555 | $82 |
| Long return visit (40+ min) | 11 | $1,535 | $90 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,235 | $88 |
| Short return visit (20+ min) | 18 | $966 | $51 |
| Short return visit (20+ min) | 17 | $538 | $32 |
2016: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $10,533 | $84 |
| Long return visit (40+ min) | 19 | $4,154 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $3,157 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $3,101 | $111 |
| Return visit (30+ min) | 28 | $3,089 | $86 |
| Return visit (30+ min) | 34 | $2,782 | $58 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 28 | $2,570 | $92 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,341 | $112 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,225 | $82 |
| New patient visit (45+ min) | 12 | $1,156 | $96 |
| New patient visit (30+ min) | 21 | $1,009 | $48 |
| New patient visit (30+ min) | 11 | $972 | $88 |
| Short return visit (20+ min) | 14 | $621 | $41 |
2015: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $3,310 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,226 | $111 |
| Return visit (30+ min) | 18 | $1,150 | $64 |
| Return visit (30+ min) | 11 | $1,086 | $84 |
| Short return visit (20+ min) | 11 | $455 | $41 |
Medicaid work
$1,959 in 2024
Medicaid paid $1,959 for 38 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 38 | $1,959 |
| 2024 | 38 | 1 | 13 | $1,959 |
| 2023 | 203 | 4 | 20 | $10,786 |
| 2022 | 68 | 2 | 16 | $2,982 |
| 2021 | 183 | 3 | 16 | $8,037 |
| 2020 | 216 | 2 | 20 | $10,676 |
| 2019 | 157 | 4 | 16 | $5,859 |
| 2018 | 31 | 1 | 13 | $1,158 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 89 | $4,742 |
| Long return visit (40+ min) | 55 | $3,185 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 46 | $2,107 |
| New patient visit (45+ min) | 13 | $751 |
2022
| Long return visit (40+ min) | 43 | $1,944 |
| Return visit (30+ min) | 25 | $1,038 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 127 | $4,669 |
| Long return visit (40+ min) | 42 | $2,817 |
| Return visit (30+ min) | 14 | $551 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 165 | $7,324 |
| Long return visit (40+ min) | 51 | $3,352 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 71 | $2,223 |
| Return visit (30+ min) | 42 | $1,603 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 31 | $1,121 |
| Long return visit (40+ min) | 13 | $911 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 31 | $1,158 |
Drugs they prescribed that Part D paid
$156,671
Pharmacies billed $156,671 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
354 generic and fewer than 11 brand-name prescriptions · $156,671 in drug cost · 42 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xifaxan | 20 | $61,657 | $3,083 |
| Vemlidy | 22 | $33,872 | $1,540 |
| Eliquis | 15 | $8,896 | $593 |
| Ursodiol | 59 | $6,880 | $117 |
| Entecavir | 20 | $2,060 | $103 |
See all 12 drugs
| Xifaxan | 20 | $61,657 | $3,083 |
| Vemlidy | 22 | $33,872 | $1,540 |
| Eliquis | 15 | $8,896 | $593 |
| Ursodiol | 59 | $6,880 | $117 |
| Entecavir | 20 | $2,060 | $103 |
| Tacrolimus | 12 | $1,450 | $121 |
| Lactulose | 20 | $586 | $29 |
| Spironolactone | 31 | $257 | $8 |
| Carvedilol | 24 | $139 | $6 |
| Furosemide | 33 | $138 | $4 |
| Prednisone | 13 | $86 | $7 |
| Omeprazole | 12 | $59 | $5 |
Year by year
| 2024 | 465 | 107 | None | None | $156,671 |
| 2023 | 503 | 100 | None | None | $176,077 |
| 2022 | 647 | 107 | None | None | $158,353 |
| 2021 | 666 | 114 | None | None | $289,641 |
| 2020 | 407 | 83 | None | None | $150,522 |
| 2019 | 542 | 101 | 0% (0) | None | $260,410 |
| 2018 | 586 | 107 | None | None | $577,101 |
| 2017 | 619 | 111 | None | None | $2,155,059 |
| 2016 | 374 | 76 | None | None | $1,427,414 |
| 2015 | 83 | 30 | None | 25% | $12,442 |
| 2014 | 43 | 18 | 0% (0) | 37% | $4,253 |
| 2013 | 40 | 20 | 0% (0) | 35% | $5,413 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Xifaxan | 15 | $50,014 | $3,334 |
| Ursodiol | 68 | $15,488 | $228 |
| Envarsus Xr | 22 | $14,284 | $649 |
| Eliquis | 16 | $9,836 | $615 |
| Tacrolimus | 31 | $4,324 | $139 |
| Mycophenolate Mofetil | 20 | $1,998 | $100 |
| Entecavir | 16 | $1,912 | $119 |
| Omega-3 Acid Ethyl Esters | 11 | $1,010 | $92 |
| Spironolactone | 18 | $372 | $21 |
| Prednisone | 26 | $350 | $13 |
| Furosemide | 37 | $266 | $7 |
| Fludrocortisone Acetate | 11 | $201 | $18 |
| Omeprazole | 26 | $201 | $8 |
| Carvedilol | 20 | $197 | $10 |
| Sulfamethoxazole-Trimethoprim | 11 | $54 | $5 |
2022: 18 drugs
| Xifaxan | 18 | $44,997 | $2,500 |
| Ursodiol | 65 | $15,698 | $242 |
| Tacrolimus | 30 | $8,239 | $275 |
| Mycophenolate Mofetil | 19 | $2,360 | $124 |
| Lactulose | 29 | $2,354 | $81 |
| Omeprazole | 51 | $399 | $8 |
| Entecavir | 12 | $376 | $31 |
| Fludrocortisone Acetate | 21 | $369 | $18 |
| Gabapentin | 18 | $351 | $20 |
| Spironolactone | 24 | $341 | $14 |
| Omega-3 Acid Ethyl Esters | 11 | $303 | $28 |
| Prednisone | 22 | $285 | $13 |
| Furosemide | 34 | $163 | $5 |
| Mirtazapine | 12 | $127 | $11 |
| Famotidine | 15 | $107 | $7 |
| Carvedilol | 15 | $90 | $6 |
| Chlorthalidone | 11 | $83 | $8 |
| Sulfamethoxazole-Trimethoprim | 16 | $78 | $5 |
2021: 16 drugs
| Xifaxan | 49 | $130,897 | $2,671 |
| Ursodiol | 72 | $11,879 | $165 |
| Tacrolimus | 33 | $8,442 | $256 |
| Lansoprazole | 19 | $1,827 | $96 |
| Fluconazole | 15 | $1,170 | $78 |
| Mycophenolate Mofetil | 13 | $995 | $77 |
| Omeprazole | 46 | $516 | $11 |
| Propranolol | 15 | $256 | $17 |
| Amiloride | 13 | $240 | $18 |
| Gabapentin | 14 | $221 | $16 |
| Prednisone | 19 | $199 | $10 |
| Carvedilol | 25 | $181 | $7 |
| Furosemide | 33 | $139 | $4 |
| Fludrocortisone Acetate | 11 | $136 | $12 |
| Metformin | 11 | $98 | $9 |
| Sulfamethoxazole-Trimethoprim | 14 | $46 | $3 |
2020: 11 drugs
| Xifaxan | 15 | $42,220 | $2,815 |
| Vemlidy | 12 | $13,933 | $1,161 |
| Ursodiol | 33 | $7,174 | $217 |
| Tacrolimus | 23 | $2,689 | $117 |
| Omeprazole | 11 | $879 | $80 |
| Amiloride | 22 | $456 | $21 |
| Spironolactone | 14 | $298 | $21 |
| Pantoprazole | 12 | $234 | $20 |
| Acyclovir | 14 | $182 | $13 |
| Gabapentin | 13 | $149 | $11 |
| Furosemide | 32 | $120 | $4 |
2019: 14 drugs
| Vemlidy | 15 | $18,584 | $1,239 |
| Ursodiol | 38 | $12,027 | $316 |
| Eliquis | 13 | $6,131 | $472 |
| Tacrolimus | 53 | $5,090 | $96 |
| Entecavir | 16 | $1,482 | $93 |
| Lactulose | 13 | $836 | $64 |
| Tenofovir Disoproxil | 12 | $730 | $61 |
| Spironolactone | 25 | $612 | $24 |
| Amiloride | 13 | $588 | $45 |
| Omeprazole | 37 | $456 | $12 |
| Pantoprazole | 22 | $337 | $15 |
| Furosemide | 38 | $284 | $7 |
| Prednisone | 11 | $104 | $9 |
| Sulfamethoxazole-Trimethoprim | 12 | $54 | $4 |
2018: 13 drugs
| Ocaliva | 15 | $95,306 | $6,354 |
| Ursodiol | 57 | $15,785 | $277 |
| Entecavir | 15 | $13,213 | $881 |
| Enoxaparin | 11 | $3,100 | $282 |
| Tacrolimus | 32 | $2,304 | $72 |
| Lactulose | 22 | $709 | $32 |
| Omeprazole | 54 | $479 | $9 |
| Fludrocortisone Acetate | 20 | $392 | $20 |
| Spironolactone | 25 | $290 | $12 |
| Furosemide | 43 | $207 | $5 |
| Mirtazapine | 20 | $127 | $6 |
| Gabapentin | 11 | $91 | $8 |
| Pantoprazole | 11 | $70 | $6 |
2017: 18 drugs
| Harvoni | 22 | $700,792 | $31,854 |
| Sovaldi | 15 | $425,197 | $28,346 |
| Daklinza | 15 | $319,873 | $21,325 |
| Epclusa | 12 | $297,317 | $24,776 |
| Zepatier | 11 | $200,597 | $18,236 |
| Xifaxan | 14 | $27,769 | $1,983 |
| Viread | 14 | $14,919 | $1,066 |
| Ursodiol | 48 | $10,720 | $223 |
| Tacrolimus | 28 | $5,444 | $194 |
| Spironolactone | 41 | $456 | $11 |
| Polyethylene Glycol 3350 | 11 | $407 | $37 |
| Lactulose | 17 | $355 | $21 |
| Omeprazole | 38 | $350 | $9 |
| Furosemide | 52 | $248 | $5 |
| Fludrocortisone Acetate | 14 | $188 | $13 |
| Pantoprazole | 15 | $184 | $12 |
| Propranolol | 15 | $164 | $11 |
| Mirtazapine | 13 | $52 | $4 |
2016: 9 drugs
| Harvoni | 21 | $657,753 | $31,322 |
| Xifaxan | 21 | $39,465 | $1,879 |
| Ursodiol | 28 | $6,887 | $246 |
| Lactulose | 27 | $391 | $14 |
| Spironolactone | 26 | $378 | $15 |
| Omeprazole | 38 | $327 | $9 |
| Propranolol | 15 | $239 | $16 |
| Furosemide | 28 | $94 | $3 |
| Pantoprazole | 12 | $90 | $7 |
2015: 3 drugs
| Omeprazole | 14 | $134 | $10 |
| Spironolactone | 14 | $110 | $8 |
| Furosemide | 12 | $26 | $2 |
Money from drug and device companies
$142 in 2025
| 2025 | 1 | 1 | None | $142 |
| 2023 | 1 | 4 | None | $22 |
| 2022 | 2 | 3 | None | $50 |
| 2021 | 1 | 1 | None | $7 |
| 2019 | 2 | 2 | None | $39 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Madrigal Pharmaceuticals | Rezdiffra | $142 | 1 payment
|
See the published payment
| Madrigal Pharmaceuticals | Meals · 2025-06-17 | Rezdiffra | $142 |
See earlier years (2023, 2022, 2021, 2019)
2023: $22
| Travere Therapeutics | Cholbam | $22 | 4 payments
|
2022: $50
| Gilead Sciences | Vemlidy | $42 | 1 payment
|
| Travere Therapeutics | Cholbam | $8 | 2 payments
|
2021: $7
| Travere Therapeutics | Cholbam | $7 | 1 payment
|
2019: $39
| Shionogi | Mulpleta | $32 | 1 payment
|
| Retrophin | (820) Cholbam | $7 | 1 payment
|
Professional record
- NPI
- 1861762619
- Licence
- CA A113664California A113664: Current · expires 2028-05-31
- Trained
- University of California, San Francisco School of Medicine, 2009
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, S101, Stanford, CA, 94305
- NPI first listed
- 2012-01-11
- NPI last updated
- 2012-01-11
This is when the NPI record was last certified, not a medical board exam.